JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
David W. Tucker, Executive Vice President and Chief Strategy Officer at Addus HomeCare Corp (NASDAQ:ADUS), recently sold 411 shares of the company’s common stock. The transaction, which took place on February 25, 2025, was executed at a price of $99.77 per share, amounting to a total of $41,005. The sale comes amid a challenging period for the stock, which has declined nearly 15% in the past week, according to InvestingPro data.
This sale was conducted under a previously established 10b5-1 plan, designed to satisfy tax obligations arising from the vesting of restricted stock awards granted by Addus HomeCare. Following the transaction, Tucker retains ownership of 11,138 shares in the company. Despite recent market pressure, the company maintains strong fundamentals with a healthy current ratio of 1.67 and operates with moderate debt levels.
The transaction was reported in a Form 4 filing with the Securities and Exchange Commission, underscoring the transparency required for insider trading activities. Addus HomeCare, based in Frisco, Texas, operates within the home health care services sector. The company has demonstrated solid performance with revenue growth of 9% in the last twelve months, though InvestingPro analysis indicates the stock is currently trading above its Fair Value. For deeper insights and access to 12 additional ProTips about ADUS, consider exploring InvestingPro’s comprehensive research report.
In other recent news, Addus HomeCare Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with an EPS of $1.38 against a forecast of $1.35 and revenue reaching $297.1 million, exceeding the projected $284.28 million. Despite these strong financial results, the company’s stock experienced a decline, which analysts attribute to broader market concerns, including potential changes in Medicaid policy. The company’s recent acquisition of Gentiva has been highlighted as a significant move, contributing to its revenue growth and strategic expansion. KeyBanc Capital Markets maintained an Overweight rating on Addus HomeCare, citing strong same-store growth and the positive impact of a rate increase in Illinois as factors for continued earnings momentum. Meanwhile, Stephens adjusted its price target for Addus HomeCare to $142 from $153, still maintaining an Overweight rating, and highlighted the company’s commitment to a growth trajectory despite uncertainties. Raymond (NSE:RYMD) James also reduced its price target to $120 from $140, while maintaining an Outperform rating, noting the company’s robust free cash flow and strong balance sheet as positive indicators. These recent developments reflect the company’s strategic efforts and the investment community’s mixed outlook amid policy uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.